



NETWORK *Notification*

Notice Date: November 9, 2023
To: Ohio Medicaid Providers
From: CareSource
Subject: Beyfortus & Synagis Billing Information for 2023-2024 RSV Season
Effective Date: November 1, 2023

Summary

Beyfortus (nirsevimab-alip) is a new monoclonal antibody indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

- Neonates and infants born during or entering their first RSV season
- Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season

For non-pharmacy providers (non-provider type 70), Beyfortus will be accepted on the medical benefit without prior authorization. Vaccines for Children (VFC) providers should submit claims with \$0 ingredient cost given product's participation in the VFC program. The following codes should be used, dose dependant:

- 90380 - Respiratory syncytial virus (RSV), monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use
- 90381 - Respiratory syncytial virus (RSV), monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use

Synagis will continue to require prior authorization through the medical benefit and will require clinical reason member is unable to use Beyfortus. The following code should be used:

- 90378 - Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each

Impact

Applicable to all Ohio Medicaid non-pharmacy providers for medical benefit billing.

Importance

All Ohio Medicaid non-pharmacy providers are advised to bill medical benefit claims for Beyfortus & Synagis per the above summary to ensure timely claims processing and payment.

Pharmacies are advised to consult Gainwell Technologies for pharmacy benefit billing guidance.

Questions?

Please contact Provider Services at **1-800-488-0134** with any questions. We are open Monday through Friday from 7 a.m. to 8 p.m. Eastern Time (ET).

Thank you for being a CareSource Provider!

OH-MED-P-2429082